Genmab Gains, Sabadell Rises, Vend Tumbles | Stock Movers
Community Score: 50% | 710 views | 1w
0 community ratings: null thumbs up, null thumbs down
Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - Genmab and AbbVie’s epcoritamab & R-CHOP combination for Diffuse large B-cell lymphoma cut the risk of disease progression or death by 51%, according to phase 3 topline data. Analysts say the positive results help de-risk sales expectations, with progression-free survival rate ahead of expected bar. - BPCE acquired a stake of about 7% in Spain’s Banco Sabadell SA as Chief Executive Officer Nicolas Namias seeks to expand business outside the French home market. - Vend Marketplaces shares fall as much as 9.7% as Nordea analysts downgrade the stock to sell from buy on the risk that consumers using AI agents to access inventory could cause the classifieds platform to lose control of traffic and monetization. See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information. Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysi
Tags: Business, Business News, Daily News, News, bloomberg, bloomberg news, business, finance, investing, investing news, markets, markets news, podcast, radio, stock, stock market, stocks, stocks podcast
More from Bloomberg Podcasts
- Follow the Money All the Way to Carney's Canada — Score: 50%
- Daybreak Weekend: US CPI, Europe Energy, RBA Decision | Bloomberg Daybreak: Europe Edition — Score: 50%
- Bloomberg Money: Credit Card Indicators and Golf's Changing Fanbase | Bloomberg Intelligence — Score: 50%
- We hear you! | Bloomberg Hot Pursuit! — Score: 50%
- Bloomberg Businessweek Weekend - August 7th, 2026 | Bloomberg Businessweek — Score: 50%
- Team Favorite: AI-Era Internet, Spaceport Investment, Bolivia’s Investability | Wall Street Week — Score: 50%